David Montoya Ossa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
David Montoya Ossa has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Oscar Mauricio Espitia Segura
Fundacion Hospital Pediatrico la Misericordia, Bogota, Colombia
3 shared publications - Juan David Farfán-Albarracín
Qualitative and Quantitative Research Network in Neuropediatrics (RICCNeP), Bogotá, Colombia; Neuropediatrics Division, HOMI Fundación Hospital Pediátrico La Misericordia, Bogotá, Colombia; School of Medicine, Universidad de Antioquia, Medellín, Colombia
2 shared publications - Nathalia Elena Penagos Vargas
Qualitative and Quantitative Research Network in Neuropediatrics (RICCNeP), Bogotá, Colombia; Neuropediatrics Division, HOMI Fundación Hospital Pediátrico La Misericordia, Bogotá, Colombia
2 shared publications - María Camila Villalba-Guerrero
Fundación Hospital Pediátrico la Misericordia
1 shared publication - Ricardo Andrés Naranjo Flórez
Fundación Hospital Pediátrico la Misericordia
1 shared publication
Latest Publications
- 21 October 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 186, 83-89
Intravenous Lacosamide in Pediatric Epilepsy: Experience From a High-Complexity Center in Bogotá, Colombia
- 21 October 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 186, 83-89
Intravenous Lacosamide in Pediatric Epilepsy: Experience From a High-Complexity Center in Bogotá, Colombia
- 6 August 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 142, 25-32
Intravenous lacosamide for pediatric status epilepticus and seizure clusters: A single-center observational study
- 6 August 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 142, 25-32
Intravenous lacosamide for pediatric status epilepticus and seizure clusters: A single-center observational study
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Journal of Inborn Errors of Metabolism and Screening
- Vol. 14
Presymptomatic Versus Late Cerliponase Alfa Therapy in CLN2 Disease: Sibling Case Report
Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rapidly progressive neurodegenerative disorder caused by TPP1 deficiency. Intracerebroventricular cerliponase alfa slows motor-language decline, although outcomes vary with disease stage at treatment initiation. Intrafamilial comparisons remain scarce, particularly in Latin America. We report two Colombian siblings carrying identical compound heterozygous TPP1 variants (c.622C>T [p.Arg208*] and c.887-10A>G) with markedly reduced enzyme activity. The older brother began enzyme replacement therapy (ERT) at age 11 with advanced neurologic impairment; whereas his sister started presymptomatically at age 3 following cascade testing. Clinical scales, neuroimaging, and cerebrospinal fluid neurofilament light (CSF NfL) levels were analyzed during 5-6 years of treatment. Before diagnosis, the brother developed language regression, ataxia, epilepsy, and visual decline. After ERT initiation, no further major motor milestone loss ocurred, seizures remained controlled, and severe disability persisted; CSF NfL decreased from 1,334 to 504 pg/mL during maintenance. His sister remained neurologically intact at age 9, with preserved motor-language function, normal MRI, and maintenance-phase CSF NfL levels of 359-531 pg/mL. These divergent intrafamilial trajectories support early TPP1 testing and prompt cascade screening in at-risk siblings, although longer follow-up is required to establish the durability of presymptomatic benefit.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Journal of Inborn Errors of Metabolism and Screening
- Vol. 14
Open AccessPresymptomatic Versus Late Cerliponase Alfa Therapy in CLN2 Disease: Sibling Case Report
Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rapidly progressive neurodegenerative disorder caused by TPP1 deficiency. Intracerebroventricular cerliponase alfa slows motor-language decline, although outcomes vary with disease stage at treatment initiation. Intrafamilial comparisons remain scarce, particularly in Latin America. We report two Colombian siblings carrying identical compound heterozygous TPP1 variants (c.622C>T [p.Arg208*] and c.887-10A>G) with markedly reduced enzyme activity. The older brother began enzyme replacement therapy (ERT) at age 11 with advanced neurologic impairment; whereas his sister started presymptomatically at age 3 following cascade testing. Clinical scales, neuroimaging, and cerebrospinal fluid neurofilament light (CSF NfL) levels were analyzed during 5-6 years of treatment. Before diagnosis, the brother developed language regression, ataxia, epilepsy, and visual decline. After ERT initiation, no further major motor milestone loss ocurred, seizures remained controlled, and severe disability persisted; CSF NfL decreased from 1,334 to 504 pg/mL during maintenance. His sister remained neurologically intact at age 9, with preserved motor-language function, normal MRI, and maintenance-phase CSF NfL levels of 359-531 pg/mL. These divergent intrafamilial trajectories support early TPP1 testing and prompt cascade screening in at-risk siblings, although longer follow-up is required to establish the durability of presymptomatic benefit.